GW cannabis-derived epilepsy drug gets positive FDA staff review
GW Pharmaceuticals' cannabis-derived medicine for severe childhood epilepsy won a favorable review from U.S. Food and Drug Administration (FDA) staff on Tuesday, boosting hopes for its approval in the world's biggest drugs market. GW's medicine Epidiolex, which is given as a syrup, is a purified form of cannabidiol, one of the active ingredients found in marijuana. It is designed to treat Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS), rare childhood-onset forms of epilepsy that are among the most resistant to treatment.